Drug Trial Radar · NCT05518318
GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)
Last checked: Nov 19, 2026Latest source record: Aug 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 2022
Primary completion
Jun 2025
Study completion Jun 2025
Sponsor
- Lead sponsor
- Guangzhou Gloria Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of GLS-010 in participants with relapsed or refractory classical Hodgkin lymphoma (R/R cHL), as measured by Progression-free Survival (PFS) as assessed by IRRC
Conditions
- Classic Hodgkin's Lymphoma
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
Interventions
GLS-010Drug
Participants receive GLS-010 240mg intravenously (IV) on Day 1, Q2W
Chemotherapy of Investigator's choiceDrug
Chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP,GEMOX, ESHAP , ICE , IGEV and GVD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) assessed by Independent Radiologic Review Committee (IRRC) per Lugano Classification 2014Time frame: Up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.